Emgality® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Emgality®▼ (galcanezumab): Use With Oral Calcitonin Gene-Related Peptide Receptor Antagonists

The safety and efficacy of concomitant use of galcanezumab with oral CGRP receptor antagonists is unknown. The use of galcanezumab with oral CGRP antagonists has not been studied.

Detailed Information

During the galcanezumab phase 3 studies for migraine prevention, oral CGRP receptor antagonists were investigational products.

Patients who were enrolled in any other clinical trial involving an investigational product were excluded from participation in galcanezumab clinical trials.1

The safety and efficacy of concomitant use of galcanezumab with oral CGRP receptor antagonists is unknown.

Galcanezumab for Migraine Prevention

Galcanezumab has been studied in migraine prevention.2-4 

Galcanezumab is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.5

Galcanezumab is a humanized IgG4 mAb that

  • binds CGRP, and

  • prevents its biological activity without blocking the CGRP receptor.2-4

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. http://dx.doi.org/10.1177/0333102418779543

3. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. http://dx.doi.org/10.1001/jamaneurol.2018.1212

4. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. http://dx.doi.org/10.1212/WNL.0000000000006640

5. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

CGRP = calcitonin gene-related peptide

IgG4 = immunoglobulin G (subclass) 4

mAb = monoclonal antibody

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: June 09, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question